Today KemPharm Inc (NASDAQ: KMPH) is trading 10.05% up.

The latest price, as of 11:57:18 est, was $6.37. KemPharm has moved $0.585 so far today.

177,314 shares have been traded today.

As of the previous close, KemPharm has a YTD change of 29.39%. The company is set to release earnings on 2022-08-11.

For technical charts, analysis, and more on KemPharm visit the company profile.

About KemPharm Inc

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

To get more information on KemPharm Inc and to follow the company's latest updates, you can visit the company's profile page here: KemPharm Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

High Hopes: Cannabis Stocks, Big Tobacco and M&A

A Closer Look at the CHIPS Act and Its Implications for the U.S. Market

China, Taiwan and the Boycott: The Data Tells the Story

An Easy Way to Profit Off One of Today’s Strongest Sectors

The Future of Smartphones is Still Unfolding: Jeff Kagan

These Stocks are Sending a Signal (Like Amazon in 2008)

It Isn’t a Recession Until This Group of Economists Says So

What You Should Know About Europe's Energy Wars